article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
List view / Grid view
Biologics
article
Drug Target Review – Issue 2 2021
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
news
Very long-chain fatty acids found to block SARS-CoV-2 infection
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
article
Challenges and opportunities in gene therapy development
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
news
New synthetic biologic could treat obesity-related diseases
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
news
Nanobody cocktail shown to block SARS-CoV-2 infection in mouse models
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
article
Which CHO cell is the right CHO cell?
Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.
whitepaper
Product hub: The world’s first BioPharma Lifecycle Management system – navigating your biopharma lifecycle
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.
news
Method for analysing sugar-protein interactions could enable better biologics
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
news
Novel DNA-based COVID-19 vaccines induce immune responses in mice
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
![A microscopy image of Leptospira bacteria [Credit: Wunder et al. (CC BY 4.0)].](https://www.drugtargetreview.com/wp-content/uploads/Leptospira-bacteria.jpg)
news
Attenuated vaccine could combat fatal Leptospira bacteria
A single vaccination with a mutated Leptospira bacteria prevented rodent models from developing leptospirosis, the most fatal type of zoonotic disease worldwide.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
Activating STING enhances CAR T-cell activity in solid tumours, shows study
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.